Summary
In recent news, genetics testing giant, 23andMe, has informed several of its users about a security breach concerning its "DNA Relatives" feature. This feature, which enables users globally to compare and share ancestry data, was infiltrated, potentially exposing sensitive information like relationship labels, ancestry reports, matching DNA segments, and more.
Main information :
- The breach was discovered after a hacker boasted about stealing millions of data pieces from 23andMe on an online platform.
- 23andMe has been actively collaborating with federal law enforcement and forensic experts to delve deeper into the matter.
- The company has communicated to its users that unauthorized access was gained to certain accounts linked via the "DNA Relatives" feature.
- Post the revelation of this breach, there's been a surge in concerns among users about the potential misuse of their ethnicity and other sensitive data.
- 23andMe has temporarily disabled certain features in the "DNA Relatives" section to prioritize user privacy during this investigation.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Data Protection Strategies for Phase III Clinical Trials
Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2
Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.
Interview Paul Chilo Director of Governance, Risk & Compliance at SOPHiA GENETICS - SOPHiA UNITY
